| B60 | Acceleration of pediatric ART regimen optimization during COVID-19 epidemic using self-learning for health care workers in Malawi | E-poster | Drug formulations for infants and children |
| B60 | Proof of principle oral dissolvable strip formulation for pediatric ARV prophylaxis | E-poster | Drug formulations for infants and children |
| B60 | Caregivers perception on paedriatic lopinavir/ritonavir formulations for HIV-infected children at Baylor Clinic, Mwanza, Tanzania | E-poster | Drug formulations for infants and children |
| B60 | Low viral suppression in children < 3 years old on two protease inhibitor formulations in Kenya, 2015-2019 | E-poster | Drug formulations for infants and children |
| B61 | Once-daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children, Week 48 results of the SMILE PENTA-17 TRIAL | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B62 | There is no substitute for hard work(ing dolutegravir): outcomes of single drug substitutions among CALHIV shifted to a dolutegravir antiretroviral regimen in Mbeya and Mwanza, Tanzania | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | High levels of drug-resistant HIV-1 among newly diagnosed antiretroviral treatment naïve infants in Uganda | E-poster | ARV management strategies in paediatric and adolescent populations |
| B62 | HIV minority resistance variants partially explain genotypic-phenotypic discordance | E-poster | ARV management strategies in paediatric and adolescent populations |